13 Analysts Have This to Say About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst ratings within the last quarter:
Regeneron Pharmaceuticals Whale Trades For October 03
Someone with a lot of money to spend has taken a bearish stance on Regeneron Pharmaceuticals (NASDAQ:REGN).
And retail traders should know.
We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.
What 13 Analyst Ratings Have To Say About Regeneron Pharmaceuticals
Within the last quarter, Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst ratings:
Analyst Ratings for Regeneron Pharmaceuticals
Within the last quarter, Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst ratings:
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Regeneron-Sanofi’s Flagship Dupixent Becomes First FDA-Approved Treatment For Prurigo Nodularis
The FDA approved Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA’s (NASDAQ:SNY) Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis. With…
Regeneron’s Dupixent Approved By FDA As First And Only Treatment Indicated For Prurigo Nodularis
Dupixent significantly reduced itch and skin lesions compared to placebo in direct-to-Phase 3 program consisting of two pivotal trials
About 75,000 adults in the U.S. living with prurigo nodularis are most in need of
Ocular Therapeutix’s Wet AMD Candidate Shows Sustained, Comparable Clinical Activity Vs. Eylea
Ocular Therapeutix Inc (NASDAQ:OCUL) announced interim 7-month data from its U.S. Phase 1 trial evaluating OTX-TKI for wet age-related macular degeneration…
$100 Invested In This Stock 10 Years Ago Would Be Worth $500 Today
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 10 years by 6.71% on an annualized basis producing an average annual return of 16.96%. Currently, Regeneron Pharmaceuticals has a market capitalization of $76.26 billion.
Europe Approves First Bispecific Antibody From Roche For Two Eye Disorders
The European Commission approved Roche Holding AG’s (OTC:RHHBY) Vabysmo (faricimab) for neovascular or ‘wet’ age-related macular degeneration (nAMD) and visual impairment…